All Updates

All Updates

icon
Filter
Partnerships
Predicine and Apollomics collaborate to develop PredicineCARE, a sequencing test for non-small cell lung cancer detection
Precision Medicine
Apr 5, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Apr 5, 2024

Predicine and Apollomics collaborate to develop PredicineCARE, a sequencing test for non-small cell lung cancer detection

Partnerships

  • Predicine has partnered with Apollomics to develop PredicineCARE, a sequencing test for detecting non-small cell lung cancer (NSCLC).

  • PredicineCARE received Breakthrough Device Designation (BDD) from the US FDA in August 2022. This cfDNA blood-based assay is claimed to be capable of examining mutations/indels, fusions, amplifications, and deletions in vital cancer-related genes using cfDNA extracted from liquid biopsy samples like blood and urine.

  • Predicine is a molecular insights company specializing in its liquid biopsy technology. The company focuses on non-invasive cancer profiling and monitoring, using cfDNA and cfRNA to detect and monitor cancer. Predicine's proprietary platforms, such as PredicineATLAS and PredicineBEACON, offer genomic profiling, aiding in early cancer detection, treatment selection, and monitoring of therapy response and disease progression.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.